Evaluate Pharma
@evaluatepharma
Followers
7K
Following
406
Media
3K
Statuses
7K
Evaluate is the trusted provider of commercial intelligence including product sales and consensus forecasts to 2028 for the global life science industry.
London, Boston & Tokyo
Joined June 2009
What makes a great forecast? Our J+D Forecasting experts focus on four key principles—Consistency, Applicability, Transparency, and Simplicity—to ensure models are easy to use, relevant, credible, and only as complex as necessary. https://t.co/xma1A2pbPv
0
0
1
ON-DEMAND WEBINAR: "Not all patent cliffs are created equal." Big Pharma faces major growth gaps as loss of exclusivity looms—but which will drop steeply and which land softly? Find out in our on-demand webinar: https://t.co/eGi89KXRPz
0
0
2
AI adoption strategies are set to surge in 50% of global healthcare companies. This is predicted to boost new drug development by 40% annually, improving efficiency in drug discovery, clinical trials, and diagnostics. Read more in this blog post: https://t.co/F9qDliJyaE
0
0
1
DOWNLOAD: The lines between pharma and biotech are blurring. As funding tightens and policy shifts, biotechs grow leaner and more independent, while pharma explores new models and direct-to-patient channels. Preview the trends in our summary: https://t.co/RS3s4hgDg9
0
0
0
Learn what makes a good (or bad) pharmaceutical forecast model, its importance, and how it aids precise decision-making in this blog post: https://t.co/xv5GE9ihH9
0
0
0
ON-DEMAND WEBINAR: $300bn in revenues are at risk from loss of exclusivity by the end of the decade. Evaluate's analysis looks at how companies can work to bridge the growth gap. https://t.co/MpK2eholC0 Check out the on-demand webinar now.
0
0
0
https://t.co/hTD2j6mrgX | There are lots of sophisticated forecasting tools out there, so why do forecasters still use Excel? In this video blog, our forecasting guru, Andrew Ward, explains more about when and why Excel still has a place in the forecaster's toolkit. Watch now.
0
0
2
Forecasting is the backbone of smart decision-making in pharma, shaping everything from manufacturing to strategy. Recently, J+D Forecasting experts, Andrew and Kris, shared actionable tips for both seasoned pros and newcomers in a free-to-view webinar. https://t.co/obuehxsDZU
0
0
1
Epidemiological forecast accuracy relies on the availability of data and the appropriate use of models. Utilizing multiple data sources like epi data, patient records and more can improve forecasts. Learn more in this blog post: https://t.co/HMO7jhHAmI
0
0
0
Turning Partnership into Purpose Watch our latest video to see how we help clients navigate industry complexity, stand out from competitors, and achieve stronger market positioning. Let Evaluate guide your journey to smarter, faster decisions. https://t.co/vYiUow7PBA
0
0
1
Many big pharma players are facing patent expiry in the next 5 years, and the pipeline is packed with competitive entrants. This forecasting report examines how the loss of exclusivity (LoE) and generic competition are influencing market planning. https://t.co/yomS5C5oe6.
0
0
1
DOWNLOAD: The lines between pharma and biotech are blurring. As funding tightens and policy shifts, biotechs grow leaner and more independent, while pharma explores new models and direct-to-patient channels. Preview the trends in our summary: https://t.co/xpgU5Nqjzv
0
0
0
Have you registered for the new Evaluate monthly newsletter yet? Don't miss out on our most-read content delivered straight to your inbox. Sign up to receive the Evaluate Discovery newsletter now! ✉️✨ https://t.co/qPo1K0qSu3
0
0
1
Today’s the day! Join our webinar at 10am ET / 3pm GMT for insights on dealmaking trends shaping biopharma. Read the blog for context: https://t.co/T8hgdxf26o Register now: https://t.co/GSFEKT4Hq9
0
0
1
🗓️ TODAY IS THE DAY! Join Evaluate’s experts as they reveal what dealmaking trends say about the future of innovation. From TL1A and TPD to next-gen RNA platforms, this is your chance to get ahead of the curve. https://t.co/Im7Aaht2U1
0
0
1
What does dealmaking reveal about the future of biopharma? Our latest blog explores the trends behind pharma partnerships and what they mean for innovation. Read it now: https://t.co/zjKBKjHGYW Join our Nov 20 webinar: https://t.co/NhaVDPzgLp
0
0
1
Happening TOMORROW! TL1A, TPD and circRNA are pharma’s next big bets. Get the data behind the dealmaking trends shaping innovation. 🕒 3 pm GMT / 10 am EST Register: https://t.co/5zb6BXCvjB
0
0
1
What does dealmaking reveal about the future of biopharma? Our latest blog explores the trends behind pharma partnerships and what they mean for innovation. Read it now: https://t.co/k6VnT6dfI3 Join our Nov 20 webinar: https://t.co/D1jkHQe2um
0
0
1
ON-DEMAND WEBINAR: Missed our live webinar? https://t.co/YXp1OmY6z8 Catch up on-demand and hear from forecasting experts on future pharma trends, challenges & opportunities. Watch Now.
0
0
1
Can your team confidently predict what’s next in pharma? Evaluate’s expert-led training—designed by J+D Forecasting—helps you solve real-world challenges with practical tools, interactive workshops, and flexible formats. Explore our training options: https://t.co/TX8W3VYBd2
0
0
1